Company / Capital Expenditures
Dare Bioscience, Inc. Capital Expenditures History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$573.0K
FY2025
5-year range
$14.5K / $629.4K
FY2021-FY2025
Trend
-9.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures has fluctuated over the past 7 years, ranging from $7,000 in FY2015 to $629,430 in FY2024.
Based on SEC 10-K filings.
$573,046 in FY2025 with a 10-year CAGR of +55.3%.
Improved from $63,069 to $573,046 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +240.4%
- 5-Year CAGR
- -
- 10-Year CAGR
- +55.3%
Key checks
Key Insights
- 3-year CAGR of +240.4%, indicating consistent growth.
- In FY2025, capital expenditures decreased 9.0% year-over-year.
- Peak capital expenditures was recorded in FY2024.
- Lowest capital expenditures in the period was in FY2015.
Company context
Key Data Points
- Altman Z-Score -2.23 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $573.0K | -9.0% |
| FY2024 | $629.4K | +898.0% |
| FY2023 | $63.1K | +334.2% |
| FY2022 | $14.5K | -93.5% |
| FY2016 | $225.0K | +3114.3% |
| FY2015 | $7.0K | -96.1% |
| FY2014 | $180.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026